<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">282481</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Klinicheskiy sluchay psevdogipoparatireoza u muzhchiny 33 let</article-title><trans-title-group xml:lang="ru"><trans-title>Клинический случай псевдогипопаратиреоза у мужчины 33 лет</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Poteshkin</surname><given-names>Yu. E</given-names></name><name xml:lang="ru"><surname>Потешкин</surname><given-names>Ю. Е</given-names></name></name-alternatives><bio xml:lang="ru"><p>ассистент кафедры эндокринологии лечебного факультета</p></bio><email>yuriy.poteshkin@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-08-20" publication-format="electronic"><day>20</day><month>08</month><year>2013</year></pub-date><volume>20</volume><issue>16</issue><issue-title xml:lang="en">NO16 (2013)</issue-title><issue-title xml:lang="ru">№16 (2013)</issue-title><fpage>92</fpage><lpage>95</lpage><history><date date-type="received" iso-8601-date="2023-02-25"><day>25</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, ООО «Бионика Медиа»</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2073-4034/article/view/282481">https://journals.eco-vector.com/2073-4034/article/view/282481</self-uri><abstract xml:lang="en"><p>Pseudohypoparathyreosis (PHP) and Albright's hereditary osteodystrophy (AHO) are very rare and heterogeneous diseases with a proven genetic component. The reasons for the development of PHP are the genetic defect of G-protein of parathyroid hormone receptor, or a defect in the intracellular signaling system of targeting cells, which lead to resistance to parathyroid hormone. The most characteristic clinical features of the AHO are brachydactyly in conjunction with heterotopic ossification; in addition, the symptoms of AHO include moon face, low height, central obesity, and varying degrees of mental retardation. Due to variety of clinical manifestations, PHP can be undetected for a long time. This clinical case is dedicated to the features of diagnosis and treatment of PHP.</p></abstract><trans-abstract xml:lang="ru"><p>Псевдогипопаратиреоз (ПГП) и наследственная остеодистрофия Олбрайта (НОО) - очень редкие и гетерогенные заболевания с доказанным генетическим компонентом. Причиной развития ПГП служит генетический дефект G-белка рецептора к паратгормону (ПТГ) или дефект во внутриклеточной сигнальной системе клеток-мишеней, которые приводят к резистентности к ПТГ. Самыми характерными клиническими признаками НОО является брахидактилия в сочетании с гетеротопической оссификацией; кроме того, симптомами НОО могут быть лунообразное лицо, низкий рост, центральное ожирение и различная степень умственной отсталости. В силу разнообразия клинических проявлений ПГП может оставаться недиагностируемым длительное время. Этот клинический случай посвящен особенностям диагностики и лечения ПГП.</p></trans-abstract><kwd-group xml:lang="en"><kwd>pseudohypoparathyreosis</kwd><kwd>hypocalcemia</kwd><kwd>Albright's osteodystrophy</kwd><kwd>resistance to parathyroid hormone</kwd><kwd>a genetic disease</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>псевдогипопаратиреоз</kwd><kwd>гипокальцемия</kwd><kwd>остеодистрофия Олбрайта</kwd><kwd>резистентность к ПТГ</kwd><kwd>генетическое заболевание</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Prevalence of rare diseases: Bibliographic data Orphanet Report Series Rare Diseases collection. June 2013, Number 1.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Albright F, Burnett CH, Smith CH, Parson W. Pseudohypoparathyroidism: an example of «Seabright-Bantam syndrome». Endocrinology 1942;30:922-32.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Tashjian Jr AH, Frantz AG, Lee JB. Pseudohypoparathyroidism: assays of parathyroid hormone and thyrocalcitonin. Proc Natl. Acad Sci USA 1966;56:1138-42.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Mann JB, Alterman S, Hills AG Albright's hereditary osteodystrophy comprising pseudohypoparathyroidism and pseudopseudohypoparathyroidism with a report of two cases representing the complete syndrome occurring in successive generations. Ann Intern Med 1962;56:315-42.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Drezner M, Neelon FA, Lebovitz HE. Pseudohypoparathyroidism type II: a possible defect in the reception of the cyclic AMP signal. N Engl J Med 1973;289:1056-60.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Potts JT. Parathyroid hormone: past and present. J Endocrinol 2005;18:311-25.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Gensure RC, Gardella TJ, Ju ppner H. Parathyroid hormone and parathyroid hormone-related peptide, and their receptors. Biochem Biophys Res Commun 2005;328:666-78.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mantovani G. Pseudohypoparathyroidism: Diagnosis and Treatment J Clin Endocrin Metab. First published ahead of print August 3, 2011 as doi:10.1210/jc.2011-1048.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Stone MD, Hosking DJ, Garcia-Himmelstine C, et al. The renal response to exogenous parathyroid hormone in treated pseudohypoparathyroidism. Bone 1993;14:727-35.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Shore EM, Ahn J, Jan De Beur S, Li M, Xu M, Gardner RJ, Zasloff MA, Whyte MP, Levine MA, Kaplan FS/ Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002;346:99-106.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Farfel Z, BrothersVM, Brickman AS, et al. Pseudohypoparathyroidism: inheritance of deficient receptor- cyclase coupling activity. Proc Natl Acad Sci USA 1981;78:3098-3102.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Fitch N. Albright's hereditary osteodistrophy: a Review. AmJ Med Genet 1982;11:11-29.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Weinberg AG, Stone RT. Autosomal dominant inheritance in Albright's haereditary osteodystrophy. J Pediatr 1971;79:996-99.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein -subunit mutations and the role of genomic imprinting. Endocr Rev 2001;22:675-705.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Levine MA, Downs Jr RW, Moses AM, et al. Resistance to multiple hormones in patients with pseudohypoparathyroidism: association with deficient activity of guanine nucleotide regulatory protein. Am J Med 1983;74:545-56.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Wemeau JL, Balavoine AS, Ladsous M, et al. Multihormonal resistance to parathyroid hormone, thyroid stimulatin hormone, and other hormonal and neurosensory stimuli in patients with pseudohypoparathyroidism. J Pediatr Endocrinol Metab 2006;19(Suppl 2):653-61.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Germain-Lee EL. Short stature, obesity, and growth hormone deficiency in pseudohypoparathyroidism type la. Pediatr Endocrinol Rev 2006;3:318-2 7.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Eyre WG, Reed WB Albright hereditary osteodystrophy with cutaneous bone formation. Arch Dermatol 1971;104:634-42.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Farfel Z, Friedman E. Mental deficiency in pseudohypoparathyroidism type I is associated with Ns-protein deficiency. Ann Intern Med 1986;105:197-99.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Wilson LC. Albright's hereditary osteodystrophy. J Pediatr Endocrinol Metab 2006; 19(Suppl 2):671-73.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Long DN, LevineMA, Germain-Lee EL. Bone mineral density in pseudohypoparathyroidism type 1a. J Clin Endocrinol Metab 2010;95:4465-75.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Levine MA, Downs Jr RW, Moses AM, et al. Resistance to multiple hormones in patients with pseudohypoparathyroidism: association with deficient activity of guanine nucleotide regulatory protein. Am J Med 1983;74: 545-56.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Barrett D, Breslau NA, Wax MB, et al. New form of pseudohypoparathyroidism with abnormal catalytic adenylate cyclase. Am J Physiol 1989;257: E277-E283.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Winter JS, Hughes IA. Familial pseudohypoparathyroidism without somatic anomalies. Can Med Assoc J 1980;123:26-31.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Nusynowitz ML, Frame B, Kolb FO. The spectrum of the hypoparathyroid states: a classification based on physiologic principles. Medicine 1976;55:105-19.</mixed-citation></ref></ref-list></back></article>
